Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors.

NCT07853105 is registered in ClinicalTrials.gov with University Hospital, Strasbourg, France as lead sponsor.

NCT NCT07853105
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07853105 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors.
Lead sponsor
University Hospital, Strasbourg, France
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
February 28, 2033
Enrollment
89 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

bone cancer, ewing sarcomas, osteosarcomas